Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols SUV39H1 and BCL11B	Name 1 SUV39H1 histone lysine methyltransferase	Name2 BCL11 transcription factor B	Pathway 1 PKMTs methylate histone lysines SIRT1 negatively regulates rRNA expression	Pathway 2 Formation of the embryonic stem cell BAF (esBAF) complex Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols SUV39H1 and FRMD6	Name 1 SUV39H1 histone lysine methyltransferase	Name2 FERM domain containing 6	Pathway 1 PKMTs methylate histone lysines SIRT1 negatively regulates rRNA expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CTBP2 and KLF3	Name 1 C-terminal binding protein 2	Name2 KLF transcription factor 3	Pathway 1 Repression of WNT target genes Signaling by TCF7L2 mutants Negative Regulation of CDH1 Gene Transcription	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CTBP2 and IKZF2	Name 1 C-terminal binding protein 2	Name2 IKAROS family zinc finger 2	Pathway 1 Repression of WNT target genes Signaling by TCF7L2 mutants Negative Regulation of CDH1 Gene Transcription	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols CTBP2 and PLCB1	Name 1 C-terminal binding protein 2	Name2 phospholipase C beta 1	Pathway 1 Repression of WNT target genes Signaling by TCF7L2 mutants Negative Regulation of CDH1 Gene Transcription	Pathway 2 PLC beta mediated events PLC beta mediated events Synthesis of IP3 and IP4 in the cytosol Acetylcholine regulates insulin secretion Acetylcholine regulates insulin secretion Ca2+ pathway G alpha (q) signalling events G alpha (q) signalling events G beta:gamma signalling through PLC beta Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Presynaptic function of Kainate receptors	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Early infantile epileptic encephalopathy; Ohtahara syndrome
Novel Novel	Symbols CTBP2 and LCORL	Name 1 C-terminal binding protein 2	Name2 ligand dependent nuclear receptor corepressor like	Pathway 1 Repression of WNT target genes Signaling by TCF7L2 mutants Negative Regulation of CDH1 Gene Transcription	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols TTC19 and FTO	Name 1 tetratricopeptide repeat domain 19	Name2 FTO alpha-ketoglutarate dependent dioxygenase	Pathway 1 Complex III assembly	Pathway 2 Reversal of alkylation damage by DNA dioxygenases	Drugs 1	Drugs 2 Artenimol	Diseases 1 Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome	Diseases 2 Growth retardation, developmental delay, coarse facies, and early death Type II diabetes mellitus
Novel Novel	Symbols MCRS1 and MIER2	Name 1 microspherule protein 1	Name2 MIER family member 2	Pathway 1 HATs acetylate histones UCH proteinases DNA Damage Recognition in GG-NER Formation of WDR5-containing histone-modifying complexes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MCRS1 and BACH2	Name 1 microspherule protein 1	Name2 BACH transcriptional regulator 2	Pathway 1 HATs acetylate histones UCH proteinases DNA Damage Recognition in GG-NER Formation of WDR5-containing histone-modifying complexes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols MCRS1 and MIER3	Name 1 microspherule protein 1	Name2 MIER family member 3	Pathway 1 HATs acetylate histones UCH proteinases DNA Damage Recognition in GG-NER Formation of WDR5-containing histone-modifying complexes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols SH3GL3 and EGFL6	Name 1 SH3 domain containing GRB2 like 3, endophilin A3	Name2 EGF like domain multiple 6	Pathway 1 EGFR downregulation Negative regulation of MET activity Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell NGF-stimulated transcription	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DMD and SGCZ	Name 1 dystrophin	Name2 sarcoglycan zeta	Pathway 1 Non-integrin membrane-ECM interactions Striated Muscle Contraction Formation of the dystrophin-glycoprotein complex (DGC) Formation of the dystrophin-glycoprotein complex (DGC)	Pathway 2 Formation of the dystrophin-glycoprotein complex (DGC) Formation of the dystrophin-glycoprotein complex (DGC)	Drugs 1 Golodirsen	Drugs 2	Diseases 1 Dilated cardiomyopathy (DCM) Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD) Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)	Diseases 2
Novel Novel	Symbols WAS and ACTR2	Name 1 WASP actin nucleation promoting factor	Name2 actin related protein 2	Pathway 1 Generation of second messenger molecules Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs CDC42 GTPase cycle RAC1 GTPase cycle RHOJ GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis	Pathway 2 Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation EPHB-mediated forward signaling RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs Neutrophil degranulation Clathrin-mediated endocytosis FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis	Drugs 1 (S)-wiskostatin	Drugs 2 N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide (2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one	Diseases 1 Neutropenic disorders, including the following three diseases: Kostmann syndrome; Cyclic neutropenia; X-linked neutropenia/myelodysplasia Thrombocytopenia (THC); Familial platelet disorder with associated myeloid malignancy (FPDMM) Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)	Diseases 2
Novel Novel	Symbols GATA1 and ZZZ3	Name 1 GATA binding protein 1	Name2 zinc finger ZZ-type containing 3	Pathway 1 RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function RUNX1 regulates transcription of genes involved in differentiation of HSCs Factors involved in megakaryocyte development and platelet production	Pathway 2 HATs acetylate histones Formation of WDR5-containing histone-modifying complexes	Drugs 1	Drugs 2	Diseases 1 Congenital dyserythropoietic anemias (CDAs) Thrombocytopenia (THC); Familial platelet disorder with associated myeloid malignancy (FPDMM)	Diseases 2
Novel Novel	Symbols ARAF and CPS1	Name 1 A-Raf proto-oncogene, serine/threonine kinase	Name2 carbamoyl-phosphate synthase 1	Pathway 1 RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	Pathway 2 Urea cycle	Drugs 1 ATP	Drugs 2 Carglumic acid	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2 Carbamoyl phosphate synthetase I deficiency
Novel Novel	Symbols AP1G1 and SYNRG	Name 1 adaptor related protein complex 1 subunit gamma 1	Name2 synergin gamma	Pathway 1 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols AP1G1 and BAALC	Name 1 adaptor related protein complex 1 subunit gamma 1	Name2 BAALC binder of MAP3K1 and KLF4	Pathway 1 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols YY1 and FOXP4	Name 1 YY1 transcription factor	Name2 forkhead box P4	Pathway 1 Activation of anterior HOX genes in hindbrain development during early embryogenesis UCH proteinases DNA Damage Recognition in GG-NER TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Estrogen-dependent gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols KLC1 and NIN	Name 1 kinesin light chain 1	Name2 ninein	Pathway 1 MHC class II antigen presentation RHO GTPases activate KTN1 COPI-dependent Golgi-to-ER retrograde traffic Signaling by ALK fusions and activated point mutants Kinesins	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols ERBB4 and EREG	Name 1 erb-b2 receptor tyrosine kinase 4	Name2 epiregulin	Pathway 1	Pathway 2 Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma Constitutive Signaling by Aberrant PI3K in Cancer Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Downregulation of ERBB2 signaling Extra-nuclear estrogen signaling Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants	Drugs 1 Afatinib Fostamatinib Brigatinib Zanubrutinib	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols SUV39H1 and BCL11B	Name 1 SUV39H1 histone lysine methyltransferase	Name2 BCL11 transcription factor B	Pathway 1 PKMTs methylate histone lysines SIRT1 negatively regulates rRNA expression	Pathway 2 Formation of the embryonic stem cell BAF (esBAF) complex Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols SUV39H1 and FRMD6	Name 1 SUV39H1 histone lysine methyltransferase	Name2 FERM domain containing 6	Pathway 1 PKMTs methylate histone lysines SIRT1 negatively regulates rRNA expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CTBP2 and KLF3	Name 1 C-terminal binding protein 2	Name2 KLF transcription factor 3	Pathway 1 Repression of WNT target genes Signaling by TCF7L2 mutants Negative Regulation of CDH1 Gene Transcription	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CTBP2 and IKZF2	Name 1 C-terminal binding protein 2	Name2 IKAROS family zinc finger 2	Pathway 1 Repression of WNT target genes Signaling by TCF7L2 mutants Negative Regulation of CDH1 Gene Transcription	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols CTBP2 and PLCB1	Name 1 C-terminal binding protein 2	Name2 phospholipase C beta 1	Pathway 1 Repression of WNT target genes Signaling by TCF7L2 mutants Negative Regulation of CDH1 Gene Transcription	Pathway 2 PLC beta mediated events PLC beta mediated events Synthesis of IP3 and IP4 in the cytosol Acetylcholine regulates insulin secretion Acetylcholine regulates insulin secretion Ca2+ pathway G alpha (q) signalling events G alpha (q) signalling events G beta:gamma signalling through PLC beta Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion Presynaptic function of Kainate receptors	Drugs 1	Drugs 2	Diseases 1	Diseases 2 Early infantile epileptic encephalopathy; Ohtahara syndrome
Novel	Symbols CTBP2 and LCORL	Name 1 C-terminal binding protein 2	Name2 ligand dependent nuclear receptor corepressor like	Pathway 1 Repression of WNT target genes Signaling by TCF7L2 mutants Negative Regulation of CDH1 Gene Transcription	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols TTC19 and FTO	Name 1 tetratricopeptide repeat domain 19	Name2 FTO alpha-ketoglutarate dependent dioxygenase	Pathway 1 Complex III assembly	Pathway 2 Reversal of alkylation damage by DNA dioxygenases	Drugs 1	Drugs 2 Artenimol	Diseases 1 Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome	Diseases 2 Growth retardation, developmental delay, coarse facies, and early death Type II diabetes mellitus
Novel	Symbols MCRS1 and MIER2	Name 1 microspherule protein 1	Name2 MIER family member 2	Pathway 1 HATs acetylate histones UCH proteinases DNA Damage Recognition in GG-NER Formation of WDR5-containing histone-modifying complexes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MCRS1 and BACH2	Name 1 microspherule protein 1	Name2 BACH transcriptional regulator 2	Pathway 1 HATs acetylate histones UCH proteinases DNA Damage Recognition in GG-NER Formation of WDR5-containing histone-modifying complexes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols MCRS1 and MIER3	Name 1 microspherule protein 1	Name2 MIER family member 3	Pathway 1 HATs acetylate histones UCH proteinases DNA Damage Recognition in GG-NER Formation of WDR5-containing histone-modifying complexes	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols SH3GL3 and EGFL6	Name 1 SH3 domain containing GRB2 like 3, endophilin A3	Name2 EGF like domain multiple 6	Pathway 1 EGFR downregulation Negative regulation of MET activity Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis InlB-mediated entry of Listeria monocytogenes into host cell NGF-stimulated transcription	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DMD and SGCZ	Name 1 dystrophin	Name2 sarcoglycan zeta	Pathway 1 Non-integrin membrane-ECM interactions Striated Muscle Contraction Formation of the dystrophin-glycoprotein complex (DGC) Formation of the dystrophin-glycoprotein complex (DGC)	Pathway 2 Formation of the dystrophin-glycoprotein complex (DGC) Formation of the dystrophin-glycoprotein complex (DGC)	Drugs 1 Golodirsen	Drugs 2	Diseases 1 Dilated cardiomyopathy (DCM) Glycerol kinase deficiency (GKD), including: Hyperglycerolemia; Chromosome Xp21 deletion syndrome; Adrenal hypoplasia, congenital (AHC); Duchenne muscular dystrophy (DMD) Dystrophinopathies, including: Duchenne muscular dystrophy (DMD); Becker muscular dystrophy (BMD); X-linked dilated cardiomyopathy (XLCM)	Diseases 2
Novel	Symbols WAS and ACTR2	Name 1 WASP actin nucleation promoting factor	Name2 actin related protein 2	Pathway 1 Generation of second messenger molecules Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs CDC42 GTPase cycle RAC1 GTPase cycle RHOJ GTPase cycle FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis	Pathway 2 Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation EPHB-mediated forward signaling RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs Neutrophil degranulation Clathrin-mediated endocytosis FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis	Drugs 1 (S)-wiskostatin	Drugs 2 N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide (2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one	Diseases 1 Neutropenic disorders, including the following three diseases: Kostmann syndrome; Cyclic neutropenia; X-linked neutropenia/myelodysplasia Thrombocytopenia (THC); Familial platelet disorder with associated myeloid malignancy (FPDMM) Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)	Diseases 2
Novel	Symbols GATA1 and ZZZ3	Name 1 GATA binding protein 1	Name2 zinc finger ZZ-type containing 3	Pathway 1 RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function RUNX1 regulates transcription of genes involved in differentiation of HSCs Factors involved in megakaryocyte development and platelet production	Pathway 2 HATs acetylate histones Formation of WDR5-containing histone-modifying complexes	Drugs 1	Drugs 2	Diseases 1 Congenital dyserythropoietic anemias (CDAs) Thrombocytopenia (THC); Familial platelet disorder with associated myeloid malignancy (FPDMM)	Diseases 2
Novel	Symbols ARAF and CPS1	Name 1 A-Raf proto-oncogene, serine/threonine kinase	Name2 carbamoyl-phosphate synthase 1	Pathway 1 RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling	Pathway 2 Urea cycle	Drugs 1 ATP	Drugs 2 Carglumic acid	Diseases 1 Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)	Diseases 2 Carbamoyl phosphate synthetase I deficiency
Novel	Symbols AP1G1 and SYNRG	Name 1 adaptor related protein complex 1 subunit gamma 1	Name2 synergin gamma	Pathway 1 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols AP1G1 and BAALC	Name 1 adaptor related protein complex 1 subunit gamma 1	Name2 BAALC binder of MAP3K1 and KLF4	Pathway 1 Nef mediated downregulation of MHC class I complex cell surface expression MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols YY1 and FOXP4	Name 1 YY1 transcription factor	Name2 forkhead box P4	Pathway 1 Activation of anterior HOX genes in hindbrain development during early embryogenesis UCH proteinases DNA Damage Recognition in GG-NER TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Estrogen-dependent gene expression	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols KLC1 and NIN	Name 1 kinesin light chain 1	Name2 ninein	Pathway 1 MHC class II antigen presentation RHO GTPases activate KTN1 COPI-dependent Golgi-to-ER retrograde traffic Signaling by ALK fusions and activated point mutants Kinesins	Pathway 2	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols ERBB4 and EREG	Name 1 erb-b2 receptor tyrosine kinase 4	Name2 epiregulin	Pathway 1	Pathway 2 Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma Constitutive Signaling by Aberrant PI3K in Cancer Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Downregulation of ERBB2 signaling Extra-nuclear estrogen signaling Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants	Drugs 1 Afatinib Fostamatinib Brigatinib Zanubrutinib	Drugs 2	Diseases 1	Diseases 2

Page 48 out of 98 pages

Search Results : Cancer